Project: A pioneering strategy to treat autoimmune diseases that enables patients to live symptom free
| Acronym | ACTION (Reference Number: 114520) |
| Duration | 01/10/2020 - 01/10/2023 |
| Project Topic | ACTION will deliver a ground-breaking therapy for autoimmune disease (AD), affecting around 600M people globally. Our first aim will be to help the 30M people with from rheumatoid arthritis (RA). The novel drug will selectively target the recently discovered endocrine – immune interface, with anticipated high efficacy rates and minimal side effects. The project will optimise the unique peptides required, delivering a compound ready for clinical trials, and potentially increase AD understanding. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 13 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Kaass Discovery | Coordinator | Norway |
| 2 | Redoxis AB | Partner | Sweden |